Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Operating Leases for 7 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 20.0% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2025, down 20.0% year-over-year, with the annual reading at $24.0 million for FY2025, 20.0% down from the prior year.
  • Operating Leases for Q4 2025 was $24.0 million at Ultragenyx Pharmaceutical, up from $21.7 million in the prior quarter.
  • The five-year high for Operating Leases was $36.8 million in Q1 2021, with the low at $14.8 million in Q2 2023.
  • Average Operating Leases over 5 years is $26.8 million, with a median of $26.8 million recorded in 2022.
  • The sharpest move saw Operating Leases plummeted 42.69% in 2023, then surged 73.4% in 2024.
  • Over 5 years, Operating Leases stood at $30.9 million in 2021, then plummeted by 35.89% to $19.8 million in 2022, then surged by 54.31% to $30.6 million in 2023, then fell by 1.88% to $30.0 million in 2024, then dropped by 20.0% to $24.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $24.0 million, $21.7 million, and $24.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.